Ultragenyx Pharmaceutical Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue - - -
Cost of Revenue - - -
Gross Profit - - -
Operating Expenses
Research and Development 27,829 12,641 4,717
Sales, General and Admin. 4,451 3,344 1,844
Non-Recurring Items - - -
Other - - -
Operating Income (32,280) (15,985) (6,561)
Income From Continuing Operations
Add'l Income/Expense Items (2,790) (349) (18)
Earnings Before Interest and Tax (35,070) (16,334) (6,579)
Interest Expense - - 270
Earnings Before Tax (35,070) (16,334) (6,849)
Income Tax - - -
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (35,070) (16,334) (6,849)
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (35,070) (16,334) (6,849)
Preferred Stock and Other Adjustments - - -
Net Income Applicable to Common Shareholders (50,289) (19,561) (7,466)